Keurig Dr Pepper 8-K 2026-11-12
KDP · CIK 1418135 · Form 8-K · Period ended November 12, 2026 · Filed November 16, 2026
1 sections, 7K characters. Original on sec.gov · ·
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026

Keurig Dr Pepper Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-33829 | 98-0517725 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
6425 Hall of Fame Lane, Frisco, Texas 75034
(Address of principal executive offices) (Zip Code)
(800) 527-7096
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|---|
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | KDP | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On November 12, 2026, Keurig Dr Pepper Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (the “Underwriters”), pursuant to which the Company agreed to sell 57,971,015 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a public offering price of $34.50 per share (the “Offering”). In connection with the Offering, the Company granted the Underwriters an option to purchase up to an additional 8,695,652 shares of Common Stock.
The Underwriting Agreement includes customary representations, warranties and covenants by the Company. It also provides that the Company will indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the complete text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 and incorporated herein by reference.
On November 16, 2026, the Company completed the Offering, including 8,695,652 shares of Common Stock sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares. The Company received approximately $2.25 billion of net proceeds from the Offering, after deducting the underwriting discount (without deducting other offering fees and expenses). The Company intends to use the net proceeds to repay or repurchase its outstanding debt, which may include borrowings under its Delayed Draw Term Loan Agreement, commercial paper notes and senior unsecured notes.
The Offering was made pursuant to the Company’s registration statement on Form S-3ASR (File No. 333-289652) (the “Registration Statement”), as supplemented by a preliminary prospectus supplement, filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2026, and a final prospectus supplement, dated November 12, 2026, filed with the SEC on November 13, 2026 pursuant to Rule 424(b) under the Securities Act. In connection with the Offering, the legal opinion as to the legality of the Common Stock sold in the Offering is being filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein and into the Registration Statement by reference.
On November 12, 2026, the Company issued press releases announcing the launch and the pricing of the Offering. Copies of the press releases are filed as Exhibits 99.1 and 99.2 hereto, respectively, and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
|---|
| Exhibit No. | Document Description | |
| 1.1 | Underwriting Agreement, dated November 12, 2026, by and among Keurig Dr Pepper Inc., Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC. | |
| 5.1 | Opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP. | |
| 23.1 | Consent of Paul, Weiss, Rifkind, Wharton & Garrison LLP (included in Exhibit 5.1). | |
| 99.1 | Press release issued by Keurig Dr Pepper Inc., dated November 12, 2026, announcing the launch of the offering. | |
| 99.2 | Press release issued by Keurig Dr Pepper Inc., dated November 12, 2026, announcing the pricing of the offering. | |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KEURIG DR PEPPER INC. | ||||
| By: | /s/ Anthony Shoemaker | |||
| Name: | Anthony Shoemaker | |||
| Title: | Chief Legal Officer, General Counsel and Secretary |
Date: November 16, 2026